Furthermore, we delved into the mechanisms underlying the effect of SA in inhibiting pneumonia in vivo and in vitro. Our research demonstrated that SA bound to Cys 151, the key action site of Keap1, and thereby activating Nrf2. The gene discussed is NFE2L2; the disease is pneumonia.